Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of “Moderate Buy” from Analysts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received a consensus rating of “Moderate Buy” from the twenty-four analysts that are covering the company, Marketbeat reports. Seven research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $279.14.

Several equities research analysts have recently commented on ALNY shares. Barclays lifted their price target on shares of Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Raymond James boosted their price objective on shares of Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Stifel Nicolaus increased their target price on shares of Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 19th. Finally, Bank of America upped their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $269.53 on Friday. The stock has a market cap of $34.09 billion, a price-to-earnings ratio of -100.57 and a beta of 0.38. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $287.55. The firm has a fifty day moving average of $265.33 and a 200-day moving average of $206.04.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. During the same quarter in the prior year, the company earned ($2.21) earnings per share. The business’s revenue was up 107.0% compared to the same quarter last year. On average, sell-side analysts predict that Alnylam Pharmaceuticals will post -2.73 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $20,563,480. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the sale, the director now directly owns 136 shares in the company, valued at approximately $35,632. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the transaction, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 57,491 shares of company stock valued at $15,446,733. 1.50% of the stock is owned by insiders.

Institutional Trading of Alnylam Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ALNY. Vanguard Group Inc. raised its stake in Alnylam Pharmaceuticals by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock valued at $1,792,542,000 after acquiring an additional 50,366 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Alnylam Pharmaceuticals by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after purchasing an additional 201,784 shares during the period. Capital International Investors lifted its stake in shares of Alnylam Pharmaceuticals by 1.8% during the 1st quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock worth $545,674,000 after buying an additional 64,560 shares during the last quarter. Capital Research Global Investors boosted its holdings in shares of Alnylam Pharmaceuticals by 7.3% during the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after buying an additional 214,908 shares during the period. Finally, Avoro Capital Advisors LLC grew its stake in Alnylam Pharmaceuticals by 9.9% in the 4th quarter. Avoro Capital Advisors LLC now owns 1,111,111 shares of the biopharmaceutical company’s stock valued at $212,678,000 after buying an additional 100,000 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.